<DOC>
	<DOCNO>NCT00907348</DOCNO>
	<brief_summary>This prospective multicenter phase II pilot trial design purpose dose find evaluate efficacy safety treatment Lenalidomide plus R-CHOP21 ( LR-CHOP21 ) elderly patient untreated Diffuse Large B Cell Lymphoma ( DLBCL ) .</brief_summary>
	<brief_title>Prospective Multicenter Dose Finding Phase II Pilot Trial Evaluate Efficacy Safety LR-CHOP21 Elderly Patients With Untreated Diffuse Large B Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>1 . Understand voluntarily sign informed consent form 2 . Able adhere study visit schedule protocol requirement 3 . Histologic subtypes follow : CD20 positive Diffuse large BCell lymphoma CD20 positive Follicular grade IIIb 4 . Age 6080 5 . Untreated patient . In patient bulky mass systemic symptom compressive disease rapidly progressive adenopathy prestudy treatment allow steroid and/or single dose Vincristine 1.4 mg/mq ( max 2 ) seven day prior start study treatment 6 . Measurable and/or evaluable disease 7 . Ann Arbor stage II , III , IV 8. International Prognostic Index lowintermediate , intermediatehigh , high risk ( 2/3/45 ) 9 . Adequate haematological count : ANC &gt; 1.5 x 109/L platelet count &gt; 75 x 109/L unless due bone marrow involvement 10 . Conjugated bilirubin 2 x UNL 11 . Alkaline phosphatase transaminases 2 x UNL 12 . Creatinine clearance &gt; 50 ml/min 13 . HIV negativity 14 . HCV negativity 15 . HBV negativity patient HBVcAb + , HbsAg , HBs Ab+/ HBVDNA negative 16 . Cardiac ejection fraction ( MUGA scan echocardiography ) &gt; 45 % 17 . Non peripheral neuropathy CNS disease . Non testicular Lymphoma 18 . Life expectancy &gt; 6 month 19 . Performance status &lt; 2 accord ECOG scale 20 . Comprehensive geriatric assessment ( CGA ) outline Appendix 15 show absence impairment activity daily living ( ADL ) , condition define geriatric syndrome , grade 4 comorbidity three grade 3 comorbidities accord CIRSG scale 21 . Disease free prior malignancy â‰¥ 3 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast 22 . Females childbearing potential ( FCBP ) must agree use two reliable form contraception simultaneously practice complete abstinence heterosexual intercourse follow time period relate study : least 28 day start study drug ; participate study ; least 28 day discontinuation study The two method reliable contraception must include one highly effective method ( i.e. , intrauterine device ( IUD ) , hormonal [ birth control pill , injection , implant ] , tubal ligation , partner 's vasectomy ) one additional effective ( barrier ) method ( i.e. , latex condom , diaphragm , cervical cap ) FCBP must refer qualified provider contraceptive method need 1 . Lymphoblastic Lymphoma 2 . Burkitt Lymphoma 3 . Non Hodgkin lymphoma CD 20 negative 4 . Mantle Cell Lymphoma 5 . Follicular Non Hodgkin Lymphoma grade IIIIIIa 6 . Primitive mediastinal diffuse large B cell lymphoma mediastinal involvement 7. International Prognostic Index low risk ( 1 ) 8 . Has know suspect hypersensitivity intolerance Rituximab 9 . History evolutive malignancy within last 3 year squamous cell basal cell carcinoma skin carcinoma situ cervix breast 10 . Extensive radiation therapy , systemic chemotherapy , antineoplastic therapy enrollment within 3 year start treatment 11 . Exposure Rituximab prior study entry 12 . Have receive experimental drug use experimental medical device within 4 week plan start treatment . Concurrent participation nontreatment study allow , interfere participation study 13 . CNS disease ( meningeal and/or brain involvement lymphoma ) Testicular involvement 14 . DVT last year 15 . History clinically relevant liver renal insufficiency ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , rheumatologic , hematologic , psychiatric , metabolic disturbance 16 . Uncontrolled diabetes ( receive antidiabetic agent , subject must stable dose least 3 month first dose study drug 17 . Uncontrolled severe cardiovascular disease include myocardial infarction within 6 month enrollment , New York Heart Association ( NYHA ) Class III IV heart failure ( Attachment 5 , NYHA Classification Cardiac Disease ) , uncontrolled angina , clinically significant pericardial disease , cardiac amyloidosis 18 . Creatinine clearance &lt; 50 ml/min 19 . Presence major neurological disorder 20 . HIV positivity 21 . HBV positivity exception patient HBVcAb + , HbsAg , HBs Ab+/ HBVDNA negative 22 . HCV positivity 23 . Active opportunistic infection 24 . Comprehensive geriatric assessment ( CGA ) outline Appendix 15 show presence impairment activity daily living ( ADL ) , condition define geriatric syndrome , grade 4 comorbidity three grade 3 comorbidities accord CIRSG scale 25 . Any coexist medical psychological condition would preclude participation study compromise ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>NHL</keyword>
	<keyword>Non Hodgkin Lymphoma</keyword>
	<keyword>Follicular Lymphoma</keyword>
</DOC>